Nanovibronix (NASDAQ:FEED – Get Free Report) and Beyond Air (NASDAQ:XAIR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Analyst Recommendations
This is a summary of current ratings and target prices for Nanovibronix and Beyond Air, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Beyond Air | 1 | 0 | 3 | 0 | 2.50 |
Beyond Air has a consensus target price of $105.00, suggesting a potential upside of 4,923.92%. Given Beyond Air’s stronger consensus rating and higher probable upside, analysts clearly believe Beyond Air is more favorable than Nanovibronix.
Risk and Volatility
Nanovibronix has a beta of 1.46, meaning that its share price is 46% more volatile than the S&P 500. Comparatively, Beyond Air has a beta of 0.21, meaning that its share price is 79% less volatile than the S&P 500.
Profitability
This table compares Nanovibronix and Beyond Air’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
| Beyond Air | -435.71% | -440.26% | -98.50% |
Insider & Institutional Ownership
16.4% of Nanovibronix shares are owned by institutional investors. Comparatively, 31.5% of Beyond Air shares are owned by institutional investors. 12.2% of Nanovibronix shares are owned by insiders. Comparatively, 10.0% of Beyond Air shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Nanovibronix and Beyond Air”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nanovibronix | $1.93 million | 0.10 | -$18.18 million | ($117.28) | -0.00 |
| Beyond Air | $7.68 million | 0.26 | -$33.25 million | ($68.40) | -0.03 |
Nanovibronix has higher earnings, but lower revenue than Beyond Air. Beyond Air is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Summary
Beyond Air beats Nanovibronix on 8 of the 14 factors compared between the two stocks.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
About Beyond Air
Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
